KALV

11.25

3.27% -0.38

Handel nachbörslich: 11.36 0.11 +0.98%

Kalvista Pharmaceuticals Inc (KALV)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$11.63

Offen:

$11.45

24-Stunden-Volumen:

621.25K

Relative Volume:

1.81

Marktkapitalisierung:

$453.33M

Einnahmen:

Nettoeinkommen (Verlust:

$-108.30M

KGV:

-3.5601

EPS:

-3.16

Netto-Cashflow:

$-97.15M

1W Leistung:

-4.58%

1M Leistung:

-0.97%

6M Leistung:

-7.25%

1J Leistung:

+29.76%

1-Tages-Spanne:

$10.78

$11.68

1-Wochen-Bereich:

$10.01

$12.85

52-Wochen-Spanne:

$7.21

$16.88

Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile

Firmenname

Kalvista Pharmaceuticals Inc

Sektor

Healthcare (1182)

Branche

Biotechnology (671)

Telefon

(857) 999-0075

Adresse

55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA

Mitarbeiter

Twitter

@kalvista

Nächster Verdiensttermin

2024-09-05

Neueste SEC-Einreichungen

KALV's Discussions on Twitter

Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2020-06-15	Eingeleitet	H.C. Wainwright	Buy
2019-07-29	Eingeleitet	SVB Leerink	Outperform
2019-03-20	Eingeleitet	Needham	Buy
2018-10-30	Eingeleitet	Jefferies	Buy
2018-09-21	Eingeleitet	Cantor Fitzgerald	Overweight
2017-08-31	Eingeleitet	BTIG Research	Buy

Alle ansehen

Kalvista Pharmaceuticals Inc Aktie (KALV) Neueste Nachrichten

07:39 AM

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - BioSpace

07:39 AM

07:29 AM

KalVista Secures $184M Financing for Sebetralstat Launch - Yahoo Finance

07:29 AM

02:29 AM

Vanguard Group Inc's Strategic Acquisition in KalVista Pharmaceu - GuruFocus.com

02:29 AM

02:11 AM

KalVista sets pricing for $60 million stock offering By Investing.com - Investing.com Canada

02:11 AM

Nov 04, 2024

KalVista Pharmaceuticals Shares Rise 11% on Royalty Financing Deal, Stock Offering - Marketscreener.com

Nov 04, 2024

DRI Healthcare Trust Announces Acquisition of a Synthetic Royalty Interest in the Worldwide Sales of Sebetralstat for the Treatment of Hereditary Angioedema Plus an Equity Investment in KalVista Pharmaceuticals - Barchart

Nov 04, 2024

Canadian Dollar/Australian Dollar (CADAUD) QuotePress Release - The Globe and Mail

Nov 04, 2024

KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million - StockTitan

Nov 04, 2024

KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust - StockTitan

Nov 04, 2024

Nov 03, 2024

KalVista Pharmaceuticals, Inc. announced that it expects to receive $5 million in funding from DRI Capital Inc. - Marketscreener.com

Nov 03, 2024

Emerald Advisers LLC Purchases 192,091 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - MarketBeat

Nov 03, 2024

Nov 02, 2024

(KALV) Long Term Investment Analysis - Stock Traders Daily

Nov 02, 2024

Oct 30, 2024

Hereditary Angioedema Market Forecasted to Surge in Coming - openPR

Oct 30, 2024

Oct 28, 2024

sebetralstat shows promise in phase 3 HAE trial By Investing.com - Investing.com South Africa

Oct 28, 2024

sebetralstat shows promise in phase 3 HAE trial - Investing.com India

Oct 28, 2024

KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology - The Bakersfield Californian

Oct 28, 2024

Oct 24, 2024

Hereditary Angioedema Market Size is Set for Rapid Growth as - openPR

Oct 24, 2024

Oct 22, 2024

(KALV) Trading Report - Stock Traders Daily

Oct 22, 2024

Oct 20, 2024

The Manufacturers Life Insurance Company Buys 3,314 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Oct 20, 2024

Oct 18, 2024

KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) - Milton Daily Standard

Oct 18, 2024

Oct 16, 2024

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest Update - MarketBeat

Oct 16, 2024

Oct 14, 2024

Plasma Protease C1 Inhibitor Market Size, Development Growth, - openPR

Oct 14, 2024

Oct 12, 2024

(KALV) Technical Data - Stock Traders Daily

Oct 12, 2024

Oct 10, 2024

Marshall Wace LLP Has $576,000 Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - MarketBeat

Oct 10, 2024

Oct 09, 2024

Sweden Hereditary Angioedema Therapeutics Market Size & Outlook, 2030 - Grand View Research

Oct 09, 2024

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stake Decreased by Dimensional Fund Advisors LP - MarketBeat

Oct 09, 2024

Oct 08, 2024

Kalvista shares hold Buy rating, price target on HAE study By Investing.com - Investing.com South Africa

Oct 08, 2024

Kalvista shares hold Buy rating, price target on HAE study - Investing.com

Oct 08, 2024

Oct 07, 2024

KalVista Pharmaceuticals (NASDAQ:KALV) Earns Buy Rating from HC Wainwright - MarketBeat

Oct 07, 2024

Kalvista asks 4 countries to OK sebetralstat as treatment for HAE - Angioedema News Today

Oct 07, 2024

Oct 05, 2024

KalVista Pharmaceuticals announces board election results - Investing.com India

Oct 05, 2024

Oct 04, 2024

KalVista Pharmaceuticals announces board election results By Investing.com - Investing.com Australia

Oct 04, 2024

Sebetralstat shows promise for anxiety in HAE attacks By Investing.com - Investing.com South Africa

Oct 04, 2024

Sebetralstat shows promise for anxiety in HAE attacks - Investing.com

Oct 04, 2024

KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum - BioSpace

Oct 04, 2024

KALVKalVista Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan

Oct 04, 2024

Oct 03, 2024